Following the success of the 1st Annual Psychedelic Therapeutics and Drug Development Conference in 2021, we're thrilled to be hosting the 2nd Annual event on May 23-24, 2022 in Washington, DC. This event has been organized to bring together the world’s leading researchers and leaders in academia, industry, the non-profit sector and government to discuss the challenges and opportunities facing those engaged in the research and development of psychedelics for various health conditions with considerable unmet need. This event will highlight the progress being made towards regulatory approval of a variety of psychedelics with the potential to treat various conditions, including inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder.

Our speakers and panelists will be covering important topics such as Clinical Trial Design, Intellectual Property, Regulatory Guidance, Psychedelic Drug Delivery, Commercialization, Legal Issues, Emerging Preclinical Science, and New Clinical Data among other topics. This event has been designed and curated for the benefit of key stakeholders in this burgeoning area and will provide practical guidance, discussion and networking.

• Clinical trial design
• Risk Evaluation & Mitigation Strategy (REMS)
• Abuse potential
• Practical use/indications
• DEA licensure & policy considerations

• Targets for novel drug development
• Dosage (micro/low/high)
• Second generation psychedelic drug design
• FDA regulatory guidance
• Toxicology studies and considerations